Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. (9th January 2019) - Wu, Y; Amonkar, M M; Sherrill, B H; O'Shaughnessy, J; Ellis, C; Baselga, J; Blackwell, K L; Burstein, H J